scinapse is loading now...

Changes in premenstrual symptoms in women starting or discontinuing use of oral contraceptives

Published on May 4, 2019in Gynecological Endocrinology 1.45
· DOI :10.1080/09513590.2018.1534097
Linda Ekenros3
Estimated H-index: 3
(Karolinska Institutet),
Torbjörn Bäckström54
Estimated H-index: 54
(Umeå University)
+ 1 AuthorsCecilia Fridén10
Estimated H-index: 10
(Karolinska Institutet)
Abstract
AbstractIt is not clear whether oral contraceptive (OC) treatment affects premenstrual symptoms in women. The aim of the present study was to evaluate changes in premenstrual symptoms (PMS) in women starting to use or discontinuing the use of OCs. Twenty-four healthy women with no previous diagnosis of premenstrual dysphoric disorder were included in this study with a prospective crossover design. Nineteen women completed daily ratings of somatic and mood symptoms during two hormonally different cycles, during a normal menstrual cycle and while using OCs. The menstrual cycle phases were hormonally verified and the low-dose, monophasic OCs were used in a 21/7 regimen. The onset of OC use significantly decreased premenstrual somatic symptoms, but it did not affect mood symptoms. In the women who discontinued OC use, no significant changes in neither somatic nor mood symptoms appeared in the premenstrual phase.
  • References (22)
  • Citations (0)
Cite
References22
Newest
Published on May 1, 2017in Fertility and Sterility 4.80
Niklas Zethraeus28
Estimated H-index: 28
(Karolinska Institutet),
Anna Dreber28
Estimated H-index: 28
(Stockholm School of Economics)
+ 5 AuthorsAngelica Lindén Hirschberg34
Estimated H-index: 34
(Karolinska Institutet)
Objective To determine whether there is a causal effect of oral contraceptive (OC) treatment on general well-being and depressed mood in healthy women. Design Double-blind, randomized, and placebo-controlled trial. Setting University hospital. Patient(s) Three hundred and forty healthy women aged 18–35 years randomized to treatment, of whom 332 completed the data collection at follow-up evaluation. Intervention(s) A combined OC (150 μg levonorgestrel and 30 μg ethinylestradiol) or placebo for 3 ...
12 Citations Source Cite
Niklas Zethraeus28
Estimated H-index: 28
(Karolinska Institutet),
Anna Dreber28
Estimated H-index: 28
(Stockholm School of Economics)
+ 5 AuthorsAngelica Lindén Hirschberg34
Estimated H-index: 34
(Karolinska University Hospital)
Context: There is a lack of knowledge about how oral contraceptives may affect sexual function. Objective: To determine whether there is a causal effect of oral contraceptives on sexuality. We hypothesized that a widely used pill impairs sexuality. Design: A double-blind, randomized, placebo-controlled trial. Enrollment began in February 2012 and was completed in August 2015. Setting: Karolinska University Hospital, Stockholm, Sweden. Participants: A total of 340 healthy women, aged 18–35 years,...
15 Citations Source Cite
Published on Oct 1, 2013in BMJ Open 2.41
Ann Josefsson23
Estimated H-index: 23
(Linköping University),
Ann-Britt Wiréhn13
Estimated H-index: 13
(Linköping University)
+ 2 AuthorsJan Brynhildsen20
Estimated H-index: 20
(Linköping University)
Objective: To investigate if continuation rates in firsttime users of oral hormonal contraceptives differed between different formulations and to measure if the rates were related to the prescribing categories, that is, physicians and midwives. Design: A longitudinal national population-based registry study. Setting: The Swedish prescribed drug register. Participants: All women born between 1977 and 1994 defined as first-time users of hormonal contraceptives from 2007 to 2009 (n=226 211). Main o...
17 Citations Source Cite
Published on Jun 1, 2013in Contraception 2.89
Sigrid Nyberg21
Estimated H-index: 21
(Umeå University)
Background: The purpose of this study was to investigate how women without and with different severity of premenstrual symptoms react to treatment with a combined oral contraceptive containing 250- ...
5 Citations Source Cite
Published on May 1, 2012in Contraception 2.89
Ellen W. Freeman56
Estimated H-index: 56
(University of Pennsylvania),
Uriel Halbreich57
Estimated H-index: 57
(State University of New York System)
+ 5 AuthorsGinger D. Constantine21
Estimated H-index: 21
BACKGROUND: This article presents an overview of four studies that evaluated a continuous oral contraceptive (OC) containing levonorgestrel (90 mcg) and ethinyl estradiol (20 mcg; LNG/EE) for managing premenstrual dysphoric disorder (PMDD) and premenstrual syndrome (PMS). STUDY DESIGN: Three randomized double-blind placebo-controlled trials and one open-label single-treatment substudy examined mean changes from baseline in the Daily Record of Severity of Problems (DRSP) or Penn Daily Symptom Rat...
32 Citations Source Cite
Published on Feb 1, 2011in Journal of Womens Health
Claudia L. Nassaralla1
Estimated H-index: 1
(Marquette University),
Joseph B. Stanford31
Estimated H-index: 31
+ 3 AuthorsRichard J. Fehring19
Estimated H-index: 19
(Marquette University)
Abstract Background: Menstrual cycle function may continue to be altered after discontinuation of oral contraceptives (OC). Few studies have been published on the effects of recent OC use on menstrual cycle parameters; none have examined characteristics of the menstrual flow or the quality of cervical mucus. The purpose of this retrospective matched cohort study is to assess biomarkers of the menstrual cycle after discontinuation of OCs. Methods: Among a sample of women who daily recorded observ...
24 Citations Source Cite
Published on Jan 1, 2011in Acta Obstetricia et Gynecologica Scandinavica 2.65
Linda Ekenros3
Estimated H-index: 3
(Karolinska Institutet),
Angelica Lindén Hirschberg34
Estimated H-index: 34
(Karolinska Institutet)
+ 1 AuthorsCecilia Fridén10
Estimated H-index: 10
(Karolinska Institutet)
Objective. This study investigates postural control among women with and without premenstrual symptoms (PMS) on oral contraceptive (OC) treatment. Design. Prospective repeated measures design. Sett ...
5 Citations Source Cite
Published on Jan 1, 2011in Ugeskrift for Læger
Mogensen Ss1
Estimated H-index: 1
,
Abild-Nielsen A1
Estimated H-index: 1
,
Bjarnason Nh1
Estimated H-index: 1
A 19 year-old female presented with sudden onset of severe headache and photophobia. Clinical examination blood tests and lumbar puncture were unremarkable.The patient was taking drospirenone/ethinyl estradiol oral contraceptives. An unenhanced computed tomography (CT) was performed with findings suspicious for sinus thrombosis. A confirmatory CT venography was made which was diagnostic for sinus thrombosis. Thrombophilia screening was performed and showed normal values. Estrogen-containing horm...
120 Citations Source Cite
Published on Jul 1, 2007in Contraception 2.89
Teri Greco2
Estimated H-index: 2
(Indiana University),
Cynthia A. Graham39
Estimated H-index: 39
(Indiana University Bloomington)
+ 2 AuthorsHelen Doll55
Estimated H-index: 55
(University of Oxford)
Purpose This study compared two oral contraceptives (OCs) with the same triphasic regimen of progestin (norgestimate 0.18, 0.215 and 0.25 mg) but differing doses of ethinyl estradiol (EE) — 25 and 35 µg EE — in their effects on androgens, mood and sexual interest in women starting on OCs. Methods Total testosterone (T), free testosterone (FT), sex-hormone-binding globulin (SHBG) and dehydroepiandrosterone sulphate (DHEA-S), together with measures of mood [Beck Depression Inventory (BDI)], sexual...
59 Citations Source Cite
Published on Dec 1, 2005in Contraception 2.89
Teri Pearlstein41
Estimated H-index: 41
(Brown University),
Gloria Bachmann41
Estimated H-index: 41
(University of Medicine and Dentistry of New Jersey)
+ 1 AuthorsKimberly A. Yonkers50
Estimated H-index: 50
(Yale University)
Abstract Purpose This multicenter, double-blind, placebo-controlled crossover study evaluated the efficacy of a new oral contraceptive (OC) formulation containing drospirenone 3 mg and ethinyl estradiol (EE) 20 μg in treating symptoms of premenstrual dysphoric disorder (PMDD). Method The OC formulation or placebo was administered for 24 days in a 28-day cycle (24/4), rather than the usual 21-day active treatment, 7-day inert-pill regimen. Participants ( N =64) were randomized to either study tre...
162 Citations Source Cite
Cited By0
Newest